Gender differences in methamphetamine-induced mRNA associated with neurodegeneration in the mouse nigrostriatal dopaminergic system.

Gender differences in methamphetamine-induced mRNA associated with neurodegeneration in the mouse nigrostriatal dopaminergic system.

Dluzen Dean E; Tweed Christopher; Anderson Linda I; Laping Nicholas J

Neuroendocrinology

2003

2003-04

In this report female and male CD-1 mice were treated with a neurotoxic regimen of methamphetamine (MA) to compare gender differences in striatal dopamine depletion and concordant changes in mRNA markers of the transforming growth factor-beta injury response associated with neurodegeneration. Striatal dopamine concentrations of MA-treated female mice were less depleted and significantly greater than that of identically treated males. Associated with this gender difference in striatal dopamine depletion were significantly decreased mRNA levels of plasminogen activator inhibitor-1 and a trend for increased (p = 0.06) mRNA levels of glial fibrillary acidic protein within females. No statistically significant differences between MA-treated female and male mice were obtained in mRNA levels for transforming growth factor-beta, transforming growth factor-beta type 2 receptor, activin-like kinase-5 or fibronectin. These data demonstrate the presence of changes in two specific molecular markers of the transforming growth factor-beta injury response which are in accordance with gender differences in

Animals; Dopamine/metabolism; Female; Inbred Strains; Male; Messenger/drug effects; Methamphetamine/*toxicity; Mice; Neostriatum/*drug effects/metabolism; Neurodegenerative Diseases/*chemically induced/genetics; Neurotoxins/*toxicity; RNA; Sex Factors; Substantia Nigra/*drug effects/metabolism

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

232–238

4

77